Suspected metastatic prostate cancer — MSRA MCQ
Instant feedback + full explanation. One question, done properly.
Educational content. Not a substitute for clinical judgement or local policy.
Reveal the answer and explanation
Correct answer: D — Arrange urgent urology or uro-oncology assessment without obtaining a prostate biopsy
Explanation lettering: E = shown as B · B = shown as C · C = shown as D · D = shown as E
This presentation gives a very high clinical suspicion of metastatic prostate cancer: a malignant-feeling prostate on DRE, markedly elevated PSA and sclerotic bone lesions. NICE recommends suspected-cancer-pathway referral when the prostate feels malignant on DRE. In the specific situation of a high PSA with radiological evidence of bone metastases, NICE advises against prostate biopsy for histological confirmation unless required for a clinical trial. Urgent specialist assessment is therefore appropriate to coordinate staging, treatment planning and symptom management. A is inappropriate because prostate MRI is not required before referral and does not supersede the biopsy exception where metastatic disease is already evident. B is the key error: biopsy can cause harm and is not routinely required in this high-suspicion metastatic presentation. D would inappropriately delay assessment; repeat testing is useful where PSA elevation may be transient or diagnostic uncertainty remains, neither of which applies here. E would be indicated urgently if there were symptoms or signs suggesting metastatic spinal cord compression, but he has no neurological deficit, sphincter disturbance or saddle sensory change.
Reference: NICE NG131: Prostate cancer: diagnosis and management — MRI and biopsy recommendations (Last updated 15 December 2021; last reviewed 13 August 2025) — https://www.nice.org.uk/guidance/ng131/chapter/Recommendations NICE NG12: Suspected cancer: recognition and referral — Prostate cancer recommendation 1.6.1 (Last updated 15 April 2026) — https://www.nice.org.uk/guidance/ng12/chapter/recommendations-organised-by-site-of-cancer